Provided by Tiger Trade Technology Pte. Ltd.

Spruce Biosciences, Inc.

72.40
+1.552.19%
Post-market: 72.400.00000.00%18:14 EST
Volume:30.00K
Turnover:2.17M
Market Cap:77.16M
PE:-0.88
High:74.40
Open:71.17
Low:71.00
Close:70.85
52wk High:240.00
52wk Low:4.28
Shares:1.07M
Float Shares:877.30K
Volume Ratio:1.28
T/O Rate:3.42%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-82.4787
EPS(LYR):-96.3944
ROE:-167.93%
ROA:-76.92%
PB:14.33
PE(LYR):-0.75

Loading ...

Company Profile

Company Name:
Spruce Biosciences, Inc.
Exchange:
NASDAQ
Establishment Date:
2014
Employees:
9
Office Location:
611 Gateway Boulevard,Suite 740,South San Francisco,California,United States
Zip Code:
94080
Fax:
- -
Introduction:
Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. The company has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses; and collaboration and license agreement with Kaken Pharmaceutical Co. Ltd. to develop, manufacture, and commercialize tildacerfont for the treatment of CAH in Japan. Spruce Biosciences, Inc. was incorporated in 2014 and is headquartered in South San Francisco, California.

Directors

Name
Position
Javier Szwarcberg
Chief Executive Officer and Director
Michael Grey
Executive Chairman
Camilla V. Simpson
Director
Daniel Spiegelman
Director
Keli Walbert
Director
Kirk Ways
Director
Percival Barretto Ko
Director

Shareholders

Name
Position
Javier Szwarcberg
Chief Executive Officer and Director
Samir Gharib
President and Chief Financial Officer